- Vantis Vascular secures $5m in funding to develop intervention technologies
- The company has received a total of $24m from high-net-worth individuals and NIH grants
- Funds will be used to advance interventional cardiology and launch the CrossFAST system
- Lead products include the CrossFAST guide extension system and CrossSHOCK IVL system
- CEO and CMO express confidence in the potential impact of their technologies
Vantis Vascular Secures Funding to Advance Intervention Technologies
Vantis Vascular has successfully secured funding to further develop its intervention technologies, marking a significant milestone in the company’s journey towards revolutionizing vascular procedures. The latest investment of $5m in a Simple Agreement for Future Equity (SAFE) financing round will play a crucial role in propelling the field of interventional cardiology forward and improving patient outcomes.
Key Details of Vantis Vascular Funding
The company’s recent funding round is convertible upon the occurrence of a future Series C preferred round, showcasing the confidence of investors in Vantis Vascular’s potential for growth and innovation. With a cumulative total of $24m raised from high-net-worth individuals and grants from the US National Institutes of Health, Vantis Vascular is well-positioned to accelerate its development efforts.
Vantis Vascular’s primary focus lies in the imminent commercial launch of its CrossFAST system, a groundbreaking integrated microcatheter guide extension system designed to enhance the delivery, safety, and efficacy of vascular procedures. The company’s lead products, including the CrossSHOCK intravascular lithotripsy (IVL) system, aim to address critical challenges in coronary interventions and improve patient outcomes significantly.
Related Video
Revolutionizing Vascular Interventions with Innovative Technologies
Vantis Vascular’s CEO, Jason Turner, expressed enthusiasm about the company’s mission to transform the medical community’s approach to treating complex and calcific arteries. The CrossFAST system, featuring the unique DuoPro Interlocking Technology, offers interventionalists enhanced control and manoeuvrability, particularly beneficial for navigating challenging anatomies with precision.
The CrossSHOCK IVL system, characterized by its low-profile microelectrode design, refines the IVL experience in treating calcified arteries, ultimately benefiting cardiovascular markets. These innovative products are poised to drive innovation in vascular interventions and make a lasting impact on patient care.
Future Growth and Innovation in Vascular Interventions
Vantis Vascular’s Chief Medical Officer, Tim Fischell, emphasized the increasing complexity of coronary interventions, highlighting the need for specialized tools to deliver life-saving therapies effectively. The company’s next-generation products hold the promise of addressing these challenges and improving outcomes for patients undergoing vascular procedures.
The recent funding secured by Vantis Vascular underscores the confidence of investors in the company’s vision, experienced management team, and the transformative potential of its technologies. With a strong focus on innovation and a commitment to driving positive change in the field of vascular interventions, Vantis Vascular is well-positioned to lead the way in advancing medical technologies for improved patient care.
Vantis Vascular’s successful funding round marks a significant step towards advancing intervention technologies and enhancing patient outcomes in the realm of vascular procedures. With a robust portfolio of innovative products and a dedicated team driving forward the company’s vision, Vantis Vascular is poised for continued growth and success in the ever-evolving landscape of medical technology.
Links to additional Resources: